Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved

Authors

DOI:

https://doi.org/10.11606/s1518-8787.2019053000879

Keywords:

Anti-Bacterial Agents, Prescription Drug Overuse, legislation & jurisprudence, Drug Resistance, Microbial, Drug Monitoring, Pharmacovigilance

Abstract

OBJECTIVE: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. METHODS: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). RESULTS: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). CONCLUSIONS: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.

Published

2019-02-07

Issue

Section

Original Articles

How to Cite

Costa, J. M. da, Moura, C. S. de, Pádua, C. A. M. de, Vegi, A. S. F., Magalhães, S. M. S., Rodrigues, M. B., & Ribeiro, A. Q. (2019). Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved. Revista De Saúde Pública, 53, 68. https://doi.org/10.11606/s1518-8787.2019053000879